These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25645432)

  • 21. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
    Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism.
    Zhao L; Zhang MJ; Zhao HY; Sun LH; Li JL; Tao B; Wang WQ; Ning G; Liu JM
    Clin Biochem; 2011 Jul; 44(10-11):844-8. PubMed ID: 21524645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs.
    Clark HE; Trepanier LA; Wood MW
    J Vet Pharmacol Ther; 2024 Jul; 47(4):274-279. PubMed ID: 38563476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum calcium (S-Ca), the forgotten test: preliminary results of an appropriateness strategy to detect primary hyperparathyroidism (pHPT).
    Salinas M; López-Garrigós M; Pomares F; Lugo J; Asencio A; López-Penabad L; Dominguez JR; Leiva-Salinas C
    Bone; 2013 Sep; 56(1):73-6. PubMed ID: 23707628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
    Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
    Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.
    Marcocci C; Chanson P; Shoback D; Bilezikian J; Fernandez-Cruz L; Orgiazzi J; Henzen C; Cheng S; Sterling LR; Lu J; Peacock M
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2766-72. PubMed ID: 19470620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature.
    Vera L; Oddo S; Di Iorgi N; Bentivoglio G; Giusti M
    J Med Case Rep; 2016 Dec; 10(1):361. PubMed ID: 27998296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
    Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
    Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ionized vs serum calcium in the diagnosis and management of primary hyperparathyroidism: which is superior?
    Tee MC; Holmes DT; Wiseman SM
    Am J Surg; 2013 May; 205(5):591-6; discussion 596. PubMed ID: 23592168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study.
    Brardi S; Cevenini G; Verdacchi T; Romano G; Ponchietti R
    Arch Ital Urol Androl; 2015 Mar; 87(1):66-71. PubMed ID: 25847900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience.
    Paruk IM; Esterhuizen TM; Maharaj S; Pirie FJ; Motala AA
    Postgrad Med J; 2013 Nov; 89(1057):626-31. PubMed ID: 23824345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice.
    Arenas MD; de la Fuente V; Delgado P; Gil MT; Gutiérrez P; Ribero J; Rodríguez M; Almadén Y
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1718-25. PubMed ID: 23463658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effects of Cinacalcet in renal stone formers with primary hyperparathyroidism].
    Vitale C; Bermond F; Rodofili A; Soragna G; Marcuccio C; Tricerri A; Marangella M
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
    de Francisco AL
    Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis.
    Díez JJ; Miguel JL; Codoceo R; Iglesias P; Bajo MA; Sánchez C; Del Peso G; Gil F; Martinez-Ara J; Gancedo PG; Selgas R
    Nephrol Dial Transplant; 2008 Apr; 23(4):1387-95. PubMed ID: 18045826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.